CASC3 and acute myeloid leukemia: Several studies investigated BTZ in combination with other cytotoxic agents against AML from the groups of anthracyclines (e.g., doxorubicin), DNA methyltransferase inhibitors (e.g., azacitidine), and histone deacetylase inhibitors (HDACI) such as vorinostat [6].